Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients

Breast Cancer Clinical Trial

Official title:

Generation of Induced Pluripotent Stem Cell Derived Cardiomyocytes From Patients Exposed to Trastuzumab Therapy for Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02772367
• Other study ID #: 16-025
• Status: Recruiting
• Start date: May 11, 2016
• Est. completion date: May 2026

Study information

• Verified date: June 2024
• Source: Memorial Sloan Kettering Cancer Center
• Contact: Angel Chan, MD, PhD
• Phone: 212-639-7217
• Email: chana5[@]mskcc.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to investigate whether cells from a biopsy taken from the patient skin can be transformed into cardiomyocytes the changes in cardiomyocyte (heart muscle cells) when grown in a special culture medium outside of the body. The structure and function of these cells will then be studied to determine why some patients with breast cancer who are treated with chemotherapy including anthracycline (e.g. Doxorubicin) and anti-HER2 therapy (e.g. Herceptin) develop decreased heart function.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: May 2026
• Est. primary completion date: May 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female

• Age greater than 18 years

• Willing to participate in protocol procedures with signed informed consent

• Assessment of LVEE via echocardiogram, cardiac MRI, or MUGA

Subjects in the cardiotoxicity group (TOX) must meet the following criteria:

• History of HER2 positive breast cancer (stage I-IV)

• Prior/current treatment with anthracycline based chemotherapy followed by anti-HER2 directed therapy or anti-HER2 directed therapy alone

• Assessment of LVEF at baseline prior to initiation of anthracycline or anti-HER2 therapy and during anti-HER2 therapy via echocardiogram, cardiac MRI, or MUGA

• Prior confirmed diagnosis of cardiotoxicity associated with anti-HER2 based therapy, defined as a decrease in LVEF > 10% from baseline to < 53% with symptoms of heart failure (NYHA class II-IV).

Subjects in the no cardiotoxicity group (NO-TOX) must meet the following criteria:

• History of HER2 positive breast cancer (stage I-IV)

• Completion of planned anthracycline and anti-HER2 therapy, or anti-HER2 therapy alone

• No symptoms of heart failure (NYHA class II-IV) during and at the end of anthracycline and anti-HER2 therapy

• Assessment of LVEF at baseline prior to innitiation of anthracycline or anti-HER2 therapy and during anti-HER2 therapy via echocardiogram, cardiac MRI, or MUGA

• Normal LVEF >53% at each assessment during and at the end of trastuzumab therapy.

• Maximum absolute decrease in LVEF <5% from baseline during and at the end of trastuzumab therapy.

• LVEF assessment performed at baseline and at least two time points during trastuzumab therapy.

Exclusion Criteria:

• Unwilling or unable to give skin biopsies

• Contraindications to punch biopsy including but not limited to bleeding diathesis, as determined by the investigator.

• Known pre-existing CV disease prior to initiation of breast cancer therapy as determined by the investigator, including

• Obstructive coronary artery disease (stenosis >70%)

• Arrhythmia - paroxysmal or persistent atrial arrhythmias, sustained ventricular tachycardia (>30 seconds), ventricular fibrillation, or cardiac arrest

• Cardiomyopathy (EF <53%)

• Heart failure (NYHA class II-IV)

• Valvular heart disease with equal to or greater than moderate stenosis or regurgitation

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Procedure:
• skin punch biopsy

Locations

Country	Name	City	State
United States	Memorial Sloan-Kettering Cancer Center	New York	New York

Sponsors (2)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center	Icahn School of Medicine at Mount Sinai

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	derive iPSs from skin fibroblasts	described by Yamanaka et al with modification using the Millipore STEMCCA excisable polycystronic lentivirus reprogramming kit.2	1 day

External Links

•   Memorial Sloan Kettering Cancer Center